TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01251172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo in vitro treated autologous peripheral blood stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Mobilization
Description: Undergo standard mobilization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Description: Undergo in vitro treated autologous peripheral blood stem cell transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study: NCT01438567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone/naloxone prolonged release (OXN PR) tablets
Description: Drug: Oxycodone/naloxone prolonged release tablets Arms: OXN PR Dosage: 2x50/25mg daily or 2x60/30mg daily or 2x70/35mg daily or 2x80/40mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone prolonged release (OxyPR) tablets
Description: Drug: Oxycodone prolonged release tablets Arms: OxyPR Dosage: 2x50mg daily or 2x60mg daily or 2x70mg daily or 2x80mg daily
Study: NCT04640324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutraceutical therapy
Description: Oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceutical therapy
Description: Oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months
Study: NCT01573117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cold crystalloid infusions, 0.9%NaCl or Ringer's solution
Description: Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
Study: NCT02434861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: P-gp substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: BCRP substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cooperstown Cocktail
Description: Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
Study: NCT03890510

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate solution
Description: Patients in both groups will receive Ringer's lactate solution continuously during operation with different infusion volume.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate solution
Description: Patients in both groups will receive Ringer's lactate solution continuously during operation with different infusion volume.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spine surgery under general Anesthesia in the prone position
Description: The surgery, general anesthesia, and the placement of the prone position will be performed according to the standard procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spine surgery under general Anesthesia in the prone position
Description: The surgery, general anesthesia, and the placement of the prone position will be performed according to the standard procedures.
Study: NCT01498861

Intervention type: DRUG
Group type: OTHER
Intervention: Ortho-Cyclen
Description: Ortho-cyclen is an oral contraceptive.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-Cyclen
Description: Ortho-cyclen is an oral contraceptive.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-Cyclen
Description: Ortho-cyclen is an oral contraceptive.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir is an experimental HIV drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir is an experimental HIV drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a tablet with no drug in it

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a tablet with no drug in it
Study: NCT04170374

Intervention type: OTHER
Intervention: Routine medical record data collection
Description: The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.

Intervention type: OTHER
Intervention: Interviews with service providers
Description: Clinicians and lay staff will be interviewed regarding the ART initiation process.
Study: NCT02486588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Messaging
Description: See detailed study description for overview of the different messaging interventions in this study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Messaging
Description: See detailed study description for overview of the different messaging interventions in this study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Messaging
Description: See detailed study description for overview of the different messaging interventions in this study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: See detailed study description for overview of the different financial incentive-based interventions in this study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: See detailed study description for overview of the different financial incentive-based interventions in this study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: See detailed study description for overview of the different financial incentive-based interventions in this study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: See detailed study description for overview of the different financial incentive-based interventions in this study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: See detailed study description for overview of the different financial incentive-based interventions in this study
Study: NCT03906968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SinuSonic Device
Description: A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion
Study: NCT01109004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenalidomide, bortezomib and dexamethasone
Description: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
Study: NCT00862680

Intervention type: PROCEDURE
Intervention: 4-Dimensional Computed Tomography
Description: Undergo 4D PET/CT

Intervention type: PROCEDURE
Intervention: 4D PET Scan
Description: Undergo 4D PET/CT scan
Study: NCT02339935

Intervention type: OTHER
Group type: OTHER
Intervention: No Brief AFA
Description: These participants will receive typical standard of care procedures while hospitalized, but will not receive the additional behavioral intervention
Study: NCT01480752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lornoxicam
Description: PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection
Study: NCT01159249

Intervention type: DRUG
Group type: OTHER
Intervention: Vildagliptin

Intervention type: DRUG
Group type: OTHER
Intervention: Vildagliptin

Intervention type: DRUG
Group type: OTHER
Intervention: Vildagliptin

Intervention type: DRUG
Group type: OTHER
Intervention: Vildagliptin
Study: NCT03505567

Intervention type: DEVICE
Group type: OTHER
Intervention: KOWA OCT Bi-µ
Description: Non-contact, ultra-high resolution ophthalmic imaging system for fundus imaging and axial cross-sectional and three-dimensional imaging of retinal structures.

Intervention type: DEVICE
Group type: OTHER
Intervention: Optovue iVue 100
Description: U.S. Food and Drug Administration (FDA) cleared and commercially available Optovue iVue 100
Study: NCT02343536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study: NCT02217319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min). After induction of anesthesia the propofol infusion is stopped and patients receive 1 MAC Sevoflurane over 30 min. Then the propofol infusion is restarted and Sevoflurane is washed out.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TIVA
Description: Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).
Study: NCT01286766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCS (docetaxel with cisplatin with TS-1)
Description: 1. S-1: 70 mg/m2 #2 bid PO, D1-14~2. Docetaxel 30 mg/m2 IVF (for 1 hr) D1 and D8~3. Cisplatin 30 mg/m2 IVF (for 2 hrs, without hydration) D1 and D8, repeated by 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCF (docetaxel with cisplatin with 5-FU)
Description: 1. 5-FU: 1,000 mg/m2 CI, D1-3~2. Docetaxel 60 mg/m2 IVF (for 1 hr) D1 followed by~3. Cisplatin 60 mg/m2 IVF (for 2 hrs, with hydration) D1, repeated by 3 weeks.~   * Intercycle or intracycle dose modification is indicated if ≥G3 hematologic toxicity (except anemia) or ≥G3 non-hematologic toxicity (except alopecia)~  * treatment is repeated until 4 cycles
Study: NCT03775369

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: endurance training
Description: physical activity and exercising (PAE)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: social support and counseling
Description: social support and counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistance training
Description: physical activity and exercising (PAE)
Study: NCT03910517

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01180153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 oxaliplatin
Description: S-1 (20mg, 25mg); L-OHP (50 mg)
Study: NCT02041104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread with added beta-glucans
Description: Participants will daily consume bread with high content of beta-glucans. They will approximately consume 6 g beta-glucans per day in 200 g of bread. Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Bread without added beta-glucans
Description: Participants will daily consume placebo bread without any added beta-glucans (approximately 200 g per day). Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics.
Study: NCT04360395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait Therapy
Description: The therapeutic gait training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed pediatric physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will consist of over-ground gait activities that will be completed in a 60 minute session with rests as needed. The key ingredients of the therapy will include: 1) activities of adequate intensity that promote gait adaptation and gait speed sustainment, 2) exploratory activities that enhance the somatosensory experience through rich/novel movement, and 3) optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints.
Study: NCT01338714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compound Herbal Formula (RHD-1)
Description: 100 ml/per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dilute RHD-1
Description: 100 ml/per day
Study: NCT01972035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Experimental Arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Standard of care
Study: NCT01739413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia
Description: Patients will be randomized to receive either epidural or general anesthesia for pain management throughout their surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia
Description: Patients will be randomized to receive either epidural or general anesthesia for pain management throughout their surgery.
Study: NCT03345758

Intervention type: OTHER
Intervention: outcome
Description: telephone to patients to finish SF-36 (the MOS item short from health survey,SF-36)，EQ-5D(EuroQol-5 Dimensions,EQ-5D)， AMT-4（Abbreviated Mental Test-4,AMT-4）and MMSE（Mini-mental State Examination,MMSE） to make assessments of their physical and mental health, cognitive function and social adaptation after discharge
Study: NCT02520791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-ICOS Monoclonal Antibody MEDI-570
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT04533139

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season antigens: A/New Caledonia/20/99(H1N1)-like, A/Wyoming/3/2003(H3N2), and B/Shanghai/361/2002-like antigens~2005-2006 season antigens: A/New Caledonia/ 20/00(H1N1)-like, A/California/7/2004 (H3N2)-like, and B/Shanghai/361/2002-like antigens

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season antigens: A/New Caledonia/20/99(H1N1)-like, A/Wyoming/3/2003(H3N2), and B/Shanghai/361/2002-like antigens~2005-2006 season antigens: A/New Caledonia/ 20/00(H1N1)-like, A/California/7/2004 (H3N2)-like, and B/Shanghai/361/2002-like antigens

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season antigens: A/New Caledonia/20/99(H1N1)-like, A/Wyoming/3/2003(H3N2), and B/Shanghai/361/2002-like antigens~2005-2006 season antigens: A/New Caledonia/ 20/00(H1N1)-like, A/California/7/2004 (H3N2)-like, and B/Shanghai/361/2002-like antigens
Study: NCT03958513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 1.5 ml 0.25% bupivacaine for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: 1.5 ml 0.9% NACl for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
Study: NCT03349736

Intervention type: OTHER
Group type: OTHER
Intervention: Pelvic Floor Muscle Training
Description: All the women will receive information and instruction/guidance exercise individually and in groups on PFMT on the first day of their visit. Following this, the women are advised to perform daily PFMT at home which includes 10 sec hold X 10 times X 3 sets. Women will record their home PFMT using an exercise diary. During the follow-up, women will attend the PFMT in a group or individual led by a Physiotherapists (to motivate and to ensure women are performing the PFMT correctly). Exercise diary will be collected in every follow up so that the information is retained even if the women discontinued or deviate from intervention protocols.
Study: NCT01646775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidural fentanyl
Description: withold epidural fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural fentanyl
Description: withold epidural fentanyl
Study: NCT02791750

Intervention type: OTHER
Intervention: questionnary of quality of life
Study: NCT06631560

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA testing
Description: Diagnostic testing was performed by testing all serum samples using the HEV ELISA Wantai and Euroimmun kit.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA testing
Description: Diagnostic testing was performed by testing all serum samples using the HEV ELISA Wantai and Euroimmun kit.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA testing
Description: Diagnostic testing was performed by testing all serum samples using the HEV ELISA Wantai and Euroimmun kit.
Study: NCT01383395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin/cilostazol
Study: NCT04319562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: needle-embedding therapy
Description: First group is comprised of Xinshu (BL15), Ganshu (BL18), Juque (CV14) bilaterally, and Xin and Gan of auricular point on the left ear. Second group includes Shentang (BL44), Hunmen (BL47), Jiuwei (RN15) bilaterally, and Xin and Gan of auricular point on the right side.~After skin cleansing with a 75% alcohol swab, intradermal thumbtack needle will be quickly inserted into the skin and embedded at acupoints mentioned above bilaterally. The needles will remain in the acupoints for 3 days and they will be removed by the therapists at next visit. This also can ensure better implementation of the blind method.Participants are required to receive this treatment twice a week. The specification of the needle used in the back shu point is φ9mm 0.20×1.5mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan), that in the auricular point is φ9mm 0.20×0.6mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: shame needle-embedding therapy
Description: The acupoint selection in this group is the same as in the needle-embedding therapy group, except that the shame intradermal needles will be used. After skin cleansing with a 75% alcohol swab, the shame intradermal needles，instead of insert into the skin, it can only stick on the surface of the skin. It also will be removed by the therapists after 3 days. This takes place twice a week. The specification of the shame needle is the same as above.
Study: NCT04220489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intraoperative ketamine and post operative 48 hour ketamine infusion with a standardized general anesthesia protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Participants will receive a 1 mg/kg dose of intravenous saline 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr saline with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure)
Study: NCT04043338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC130-A10H
Description: XC130-A10H supplied as a 0.2, 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules or tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplied as matching capsules or tablets
Study: NCT02392039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Group 1 - Cycles 1 and 3: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 2 and 4: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Group 1 - Cycles 1 and 3: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 2 and 4: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.